Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Overall Survival
52%
Chemotherapy
48%
Confidence Interval
45%
Lung Cancer
44%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
44%
Phase II Study
36%
Phase I Study
36%
Small Cell Lung Cancer
35%
Tumor
34%
NCCTG
31%
Cancer Treatment
31%
Phase II Trial
30%
Programmed Death-ligand 1 (PD-L1)
30%
Treatment Group
28%
North Central
28%
Immune Checkpoint Inhibitors
27%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
26%
Pemetrexed
26%
Maximum Tolerated Dose
25%
Adverse Events
25%
Carboplatin
24%
Progression-free Survival
23%
Pazopanib
22%
Clinical Trials
21%
Hazard Ratio
21%
Advanced Solid Tumors
20%
Lung Cancer Treatment
20%
Partial Response
19%
Stable Disease
18%
Malignant Pleural Mesothelioma
18%
Sorafenib
18%
Pulmonary Carcinoid Tumor
18%
In Cancer
16%
Mayo Clinic
16%
Lung Cancer Patients
16%
Tolerability
16%
Single Institution
15%
Immunohistochemistry
15%
Anaplastic Thyroid Cancer
15%
Lung Cancer Cells
14%
Patients with Advanced Cancer
14%
Erlotinib
14%
Meta-analysis
13%
PFKFB3
13%
Systematic Meta-analysis
13%
Cisplatin
12%
Tumor Response
12%
Mesothelioma
12%
Pembrolizumab
12%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
91%
Malignant Neoplasm
69%
Neoplasm
65%
Lung Cancer
61%
Chemotherapy
53%
Small Cell Lung Cancer
48%
Diseases
48%
Solid Malignant Neoplasm
38%
Overall Survival
37%
Adverse Event
35%
Progression Free Survival
35%
Clinical Trial
30%
Maximum Tolerated Dose
29%
Pemetrexed
28%
Pharmacokinetics
28%
Treatment Group
28%
Carboplatin
24%
Pazopanib
22%
Biological Marker
19%
Sorafenib
18%
Epidermal Growth Factor Receptor
17%
Survival Rate
16%
Tolerability
16%
Carcinogenesis
15%
Advanced Cancer
14%
Paclitaxel
14%
Erlotinib
14%
Pancreas Cancer
14%
Topotecan
13%
Immune Checkpoint Inhibitor
13%
Protein Tyrosine Kinase Inhibitor
12%
Antitumor Activity
11%
Diarrhea
11%
Monotherapy
11%
Cisplatin
10%
Mammalian Target of Rapamycin Inhibitor
10%
Phase II Trials
10%
Differentiated Thyroid Cancer
10%
Docetaxel
10%
Anaplastic Lymphoma Kinase
10%
Nausea
10%
Anaplastic Thyroid Carcinoma
10%
Messenger RNA
10%
Bevacizumab
9%
Bortezomib
9%
Phosphotransferase Inhibitor
9%
Pleura Mesothelioma
9%
Esophageal Adenocarcinoma
9%
Barrett Esophagus
9%
Pralatrexate
9%
Medicine and Dentistry
Neoplasm
62%
Non Small Cell Lung Cancer
59%
Lung Cancer
49%
Small Cell Lung Cancer
48%
Overall Survival
38%
Malignant Neoplasm
29%
Diseases
28%
Cancer Therapy
26%
Progression Free Survival
23%
Cancer
22%
Mesothelioma
20%
Treatment Group
19%
Pleura Mesothelioma
15%
Epidermal Growth Factor Receptor
15%
Survival Rate
15%
Lung
14%
Cisplatin
13%
Pulmonary Carcinoid Tumour
13%
Pazopanib
13%
Placebo
13%
Thymus Cancer
13%
Hazard Ratio
13%
Pemetrexed
13%
Carcinoid
13%
Clinical Trial
12%
Adverse Event
12%
Carboplatin
12%
Metastatic Carcinoma
12%
Radiation Therapy
12%
Immunotherapy
11%
Methylation
11%
Thymic Carcinoma
10%
Neuroendocrine Tumor
9%
Anaplastic Thyroid Carcinoma
9%
Cancer Growth
9%
Anaplastic Lymphoma Kinase
9%
Biopsy Technique
9%
Radioactive Iodine
9%
Differentiated Thyroid Cancer
9%
Programmed Death 1 Ligand 1
9%
Lung Adenocarcinoma
9%
Biological Marker
8%
Carcinogenesis
8%
Programmed Cell Death
8%
Tumor Progression
8%
Xenograft
7%
Interim Analysis
7%
Neoadjuvant Chemotherapy
7%
Quality of Life
7%
Systemic Therapy
7%